Niaspan
ApprovedSmall molecule
Merck & Co.Niaspan is one of 152 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
4
Indications
11
Total Trials
0
Active Trials
151
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
223 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Leqvio
NovartisPhase 3
Vanrafia
NovartisPhase 3
Zetia
OOrganon and Co
Phase 3
Tekturna
Tibotec Pharmaceuticals, IrelandPhase 3
Niaspan
Merck & Co.Approved
Kynamro
KKastle Therapeutics, LLC
Phase 3
Glutamine
SanofiPhase 3
Praluent
RegeneronPreclinical
Repatha
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Interaction1 trial
Peripheral Arterial Disease1 trial
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Completed·—·Phase 4·NCT00687076·102 enrolled
Atherosclerosis1 trial
6 more indications
Women1 trial
Benefit of Elevation of HDL-C in Women
Completed·—·Phase 4·NCT01921010·43 enrolled
Cardiovascular1 trial
Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
Completed·—·Phase 4·NCT00590629·43 enrolled
Coronary Artery Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Niaspan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company